Skip to main content

Table 1 Patient characteristics

From: Phase I clinical study of the recombinant antibody toxin scFv(FRP5)-ETA specific for the ErbB2/HER2 receptor in patients with advanced solid malignomas

Patient Age (years), sex Cancer type Stage at diagnosis/surgery Sites of metastasis Prior therapy
N01 61, female Head and neck T2N2bMX Local, intrapulmonal, mediastinal Surgery, radiation, chemotherapy
U01 61, female Breast T2N2M1 Liver, bone Surgery, chemotherapy, herceptin
U02 56, female Breast T4N1bM0 Lymph node, liver, central nervous system, skin, bone Surgery, radiation, chemotherapy, herceptin
U03 68, female Breast T3N1M0 Lymph node, bone Surgery, radiation, chemotherapy, herceptin, hormonal therapy
U04 64, female Breast T3N0M0 Local, skin, bone, intrapulmonal Surgery, chemotherapy, herceptin
U05 71, female Breast T1aN3cM1 Lymph node, skin Surgery, chemotherapy, herceptin
N03 63, female Breast T3N1bM0 Liver Surgery, chemotherapy, herceptin
N04 55, male Transitional cell carcinoma TXNXMX Lymph node Surgery, chemotherapy, herceptin
N05 72, male Prostate T4N3M1 Lymph node, bone, other Surgery, hormonal therapy
N06 63, male Prostate T2bN0M0 Lymph node Surgery, chemotherapy, hormonal therapy
N07 74, female Breast T1N0M0 Liver Surgery, radiation, hormonal therapy
N09 50, female Breast T1N0M0 Lymph node, liver, bone, intrapulmonal, pleural Surgery, chemotherapy
N10 45, female Breast T3bN1bMX Bone Surgery, radiation, chemotherapy, herceptin
N12 69, female Breast T4N3M1 Local, lymph node, skin Chemotherapy, hormonal therapy, immunotherapy
N13 46, female Breast TXNXMX Lymph node, liver, central nervous system, skin, bone Surgery, radiation, chemotherapy, herceptin
N14 82, female Breast TXNXMX Liver, pleural Surgery, hormonal therapy
N15 70, female Breast T2N1MX Lymph node, skin, bone Surgery, radiation, chemotherapy, herceptin
N17 62, male Non small cell lung carcinoma T2cN2cM1 Lymph node, bone, intrapulmonal Patient refused standard therapy